[Vaccination approach in patients with an allergic reaction to COVID-19 vaccines or at risk of developing allergic reactions].

IF 0.7 Q4 RESPIRATORY SYSTEM Tuberkuloz ve Toraks-Tuberculosis and Thorax Pub Date : 2023-06-01 DOI:10.5578/tt.20239920
Şeyma Özden, Fatma Merve Tepetam, Özge Atik
{"title":"[Vaccination approach in patients with an allergic reaction to COVID-19 vaccines or at risk of developing allergic reactions].","authors":"Şeyma Özden, Fatma Merve Tepetam, Özge Atik","doi":"10.5578/tt.20239920","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There is consensus that patients at risk of developing an allergic reaction to COVID-19 vaccines should be evaluated by an immunologist-allergist to determine whether vaccination should be recommended. We wanted to share our experiences in the management of these high-risk patients, from diagnostic tests in allergological evaluation to the vaccination process.</p><p><strong>Materials and methods: </strong>Our retrospective cross-sectional study included patients who had previously developed an allergic reaction to COVID-19 vaccines or drugs and therefore were referred to our allergy and immunology clinic. Prick and intradermal tests were performed on all patients with methylprednisolone acetate (Depo-Medrol®, Pfizer) 40 mg/mL containing polyethylene Glycol (PEG) and triamcinolone acetonide (Kenacort®, Deva) 40 mg/mL containing polysorbate 80. While vaccination with desensitization was recommended for all patients with positive skin tests, split-dose vaccination was recommended for patients with negative skin tests. After explaining the risks and benefits, the choice of the vaccine (Pfizer/BioNTech or Sinovac/ CoronoVac) was left to the patients' discretion.</p><p><strong>Result: </strong>A total of 41 patients, 10 males, and 31 females, with a mean age of 42.37 ± 14.177 years were included. Eighteen patients with a history of allergy after COVID-19 vaccines were analyzed according to the type of reaction and type of vaccine administered (Pfizer/BioNTech/Coronovac; Anaphylaxis: 4/1, Urticaria: 11/2). Moreover, there was a history of drug allergy in 23 patients who had not been vaccinated before. Skin tests with PEG were positive in a total of seven patients while skin tests with polysorbate 80 were negative in all patients. No allergic reaction developed in seven patients who underwent desensitization and in 34 patients who received a split dose.</p><p><strong>Conclusions: </strong>Considering the potentially life-saving benefits of vaccination in a global pandemic environment, it is a safe and effective method to administer vaccines to at-risk patients using desensitization or split dosing techniques, based on their sensitivity status determined through a PEG skin test. This approach allows for the avoidance of preventing access to vaccines, while still ensuring the safety of patients.</p>","PeriodicalId":45521,"journal":{"name":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10795276/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberkuloz ve Toraks-Tuberculosis and Thorax","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5578/tt.20239920","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: There is consensus that patients at risk of developing an allergic reaction to COVID-19 vaccines should be evaluated by an immunologist-allergist to determine whether vaccination should be recommended. We wanted to share our experiences in the management of these high-risk patients, from diagnostic tests in allergological evaluation to the vaccination process.

Materials and methods: Our retrospective cross-sectional study included patients who had previously developed an allergic reaction to COVID-19 vaccines or drugs and therefore were referred to our allergy and immunology clinic. Prick and intradermal tests were performed on all patients with methylprednisolone acetate (Depo-Medrol®, Pfizer) 40 mg/mL containing polyethylene Glycol (PEG) and triamcinolone acetonide (Kenacort®, Deva) 40 mg/mL containing polysorbate 80. While vaccination with desensitization was recommended for all patients with positive skin tests, split-dose vaccination was recommended for patients with negative skin tests. After explaining the risks and benefits, the choice of the vaccine (Pfizer/BioNTech or Sinovac/ CoronoVac) was left to the patients' discretion.

Result: A total of 41 patients, 10 males, and 31 females, with a mean age of 42.37 ± 14.177 years were included. Eighteen patients with a history of allergy after COVID-19 vaccines were analyzed according to the type of reaction and type of vaccine administered (Pfizer/BioNTech/Coronovac; Anaphylaxis: 4/1, Urticaria: 11/2). Moreover, there was a history of drug allergy in 23 patients who had not been vaccinated before. Skin tests with PEG were positive in a total of seven patients while skin tests with polysorbate 80 were negative in all patients. No allergic reaction developed in seven patients who underwent desensitization and in 34 patients who received a split dose.

Conclusions: Considering the potentially life-saving benefits of vaccination in a global pandemic environment, it is a safe and effective method to administer vaccines to at-risk patients using desensitization or split dosing techniques, based on their sensitivity status determined through a PEG skin test. This approach allows for the avoidance of preventing access to vaccines, while still ensuring the safety of patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[对 COVID-19 疫苗有过敏反应或有发生过敏反应风险的患者的疫苗接种方法]。
导言:目前的共识是,有可能对 COVID-19 疫苗产生过敏反应的患者应由免疫过敏学家进行评估,以确定是否建议接种疫苗。我们希望分享我们在管理这些高风险患者方面的经验,包括从过敏学评估中的诊断测试到疫苗接种过程:我们的回顾性横断面研究包括曾对 COVID-19 疫苗或药物产生过敏反应并因此被转诊至过敏与免疫诊所的患者。所有患者均接受了含有聚乙二醇(PEG)的醋酸甲泼尼龙(Depo-Medrol®,辉瑞公司)40 毫克/毫升和含有聚山梨醇酯 80 的曲安奈德(Kenacort®,Deva 公司)40 毫克/毫升的刺穿试验和皮内试验。建议所有皮试呈阳性的患者接种脱敏疫苗,而皮试呈阴性的患者则分剂量接种。在解释了风险和益处后,患者可自行选择疫苗(辉瑞/BioNTech 或 Sinovac/CoronoVac):共纳入 41 名患者,其中男性 10 人,女性 31 人,平均年龄(42.37 ± 14.177)岁。根据反应类型和接种疫苗类型(辉瑞/BioNTech/Coronovac;过敏性休克:4/1;荨麻疹:11/2),对 18 名接种 COVID-19 疫苗后有过敏史的患者进行了分析。此外,有 23 名患者有药物过敏史,但之前未接种过疫苗。共有 7 名患者的 PEG 皮肤试验呈阳性,而所有患者的聚山梨醇酯 80 皮肤试验均呈阴性。7 名接受脱敏治疗的患者和 34 名接受分次剂量治疗的患者均未出现过敏反应:考虑到在全球大流行环境中接种疫苗有可能挽救生命,根据通过聚山梨醇酯 80 皮肤测试确定的敏感状况,采用脱敏或分次给药技术为高危患者接种疫苗是一种安全有效的方法。这种方法既能避免疫苗接种受阻,又能确保患者的安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.50
自引率
9.10%
发文量
43
期刊最新文献
A patient with widespread skin lesions presenting with massive pleural effusion. A perspective on the scope of videoconferencing-based telemedicine in respiratory diseases outpatient clinic. Analysis of one-year follow-up results and treatment costs of patients with PTE in a tertiary care center. Analysis of post-COVID symptoms and predisposing factors for chronic post-COVID syndrome. Characteristics of adverse reactions due to subcutaneous allergen immunotherapy applied between 2011-2021: Single center experience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1